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Abstract
Histone deacetylase (HDAC) inhibitors are a new class of chemotherapeutic agents. Our
laboratory has recently reported that phenylhexyl isothiocyanate (PHI), a synthetic isothiocyanate,
is an inhibitor of HDAC. In this study we examined whether PHI is a hypomethylating agent and its
effects on myeloma cells. RPMI8226, a myeloma cell line, was treated with PHI. PHI inhibited the
proliferation of the myeloma cells and induced apoptosis in a concentration as low as 0.5 μM. Cell
proliferation was reduced to 50% of control with PHI concentration of 0.5 μM. Cell cycle analysis
revealed that PHI caused G1-phase arrest of RPMI8226 cells. PHI induced p16 hypomethylation in
a concentration- dependent manner. PHI was further shown to induce histone H3 hyperacetylation
in a concentration-dependent manner. It was also demonstrated that PHI inhibited IL-6 receptor
expression and VEGF production in the RPMI8226 cells, and reactivated p21 expression. It was
found that PHI induced apoptosis through disruption of mitochondrial membrane potential. For the
first time we show that PHI can induce both p16 hypomethylation and histone H3 hyperacetylation.
We conclude that PHI has dual epigenetic effects on p16 hypomethylation and histone
hyperacetylation in myeloma cells and targets several critical processes of myeloma proliferation.
Background
Despite many recent advances in treatment, multiple
myeloma (MM) remains as an incurable disease without
an allogeneic hematopoietic cell transplantation. The
emergence of drug resistance and incomplete responses
have been the major obstacles for improving the treat-
ment results [1,2]. The new treatment strategies have been
based largely upon targeting specific molecules or path-
ways, such as proteosome inhibitors and thalidomide
analogs. Aberrant methylation of gene promoter regions
is a widely studied epigenetic process in malignant disor-
ders. Cell cycle inhibitors of p15 and p16 are the tumor
suppressor genes frequently affected by this epigenetic
change [3,4]. The aberrant methylation of gene promoter
regions is associated with loss of gene function. In addi-
tion to gene deletions and mutations, quantitative
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changes in gene methylation status play a significant role
in tumorigenesis [5]. Hypermethylation of p15 and p16
promoter CpG islands has been reported in MM clinical
specimens and myeloma cell lines [4,6,7]. The methyla-
tion status of p15 and p16 genes were not significantly dif-
ferent between MM and MGUS (monoclonal
gammopathy of unknown significance) nor in pre-treated
and post-treated patients with MM [6-8]. It was further
demonstrated in MM patients that p16 hypermethylation
is associated with high plasma cell proliferation, higher
β2-microglobulin concentration, and shorter survival,
whereas no such clear correlation was found with p15
CpG island hypermethylation [4,7,9].
The proliferation and survival of myeloma cells are also
potentiated by IL-6 and IL-6 receptor signal transduction
through autocrine and paracrine stimulation [10,11].
Exogenous IL-6 was able to block the apoptosis induced
by the chemotherapeutic agent dexamethasone [10,12].
Increased angiogenesis and microvascular density in the
bone marrow microenvironment correlate with poor
prognosis and drug resistance of myeloma cells [13-15].
Cytokines that augment angiogenesis are known to be
present at elevated levels in the bone marrow. The vascu-
lar endothelial growth factor (VEGF) is one of those ele-
vated cytokines associated with angiogenesis.
Thalidomide and its derivative, lenalidomide (CC-5013,
Revlimid; Celgene), are inhibitors of angiogenesis and are
widely used for MM therapy [1].
In the search for novel molecular targets, histone deacety-
lases (HDACs) that affect epigenetic processes have
emerged as one of the potential targets [16,17]. Recent
studies have indicated that the expression of various genes
that regulate differentiation, proliferation, and apoptosis
are also influenced by HDACs. Aberrant histone acetyla-
tion appears to play an important role in the development
of numerous malignancies [18,19]. Agents that modify
histone acetylation thus show great promise against vari-
ous malignancies [20-26]. Vorinostat (Suberoylanilide
hydroxamic acid, SAHA, Zolinza; Merck) is among the
first HDAC inhibitors approved for clinical treatment of
cutaneous T cell lymphoma [27,28]. Our laboratory has
recently reported that a synthetic isothiocyanate, phenyl-
hexyl isothiocyanate (PHI), is an inhibitor of HDACs
[29,30]. We have found that PHI can induce selective his-
tone acetylation and lead to cell cycle arrest and apoptosis
in human leukemia cells and prostate cancer cells [29-31].
Oral feeding of PHI to immunodeficient mice inhibited
the tumorigenesis of human leukemia cells in vivo
[29,30]. We have further demonstrated that PHI has a
selective effect in inducing apoptosis in cancer cells, but
not in normal cells [29-31]. In this study we demon-
strated, for the first time, that PHI has dual epigenetic
effects of causing histone hyperacetylation and p16
hypomethylation in multiple myeloma cell line
RPMI8226.
Methods
Cell culture and chemicals
The preparation of PHI has been described previously
[29,30]. Human myeloma cell line RPMI 8226 was
obtained from American Type Culture Collection (ATCC,
Manassas, VA). Cells were seeded at 0.3 × 106 per ml of
RPMI-1640 medium, supplemented with 10% heat-inac-
tivated fetal calf serum, 100 IU penicillin/ml and 100 ug
streptomycin/ml, and maintained at 37°C in a humidi-
fied atmosphere containing 5% CO2. Cells in exponential
growth were exposed to PHI at various concentrations
prepared in 75% methanol and PBS [29]. The control cul-
tures were supplemented with the methanol-containing
medium. Cell viability was determined from at least trip-
licate cultures by trypan blue exclusion method. Cell den-
sity was calculated by the viable cell counts per ml.
Methylation specific PCR
Methylation specific PCR (MS-PCR) was performed using
the procedure previously described [32]. RPMI 8226 cells
at exponential growth were treated without or with PHI or
Decitabine at various concentrations for 10 days. The
DNA from the cells was extracted and bisulfite-converted
for MS-PCR analyses. The primers for the methylated form
of p16 are ttattagagggtggggcggatcgc (sense) and gac-
cccgaaccgcgaccgtaa (antisense). The primers for unmethyl-
ated form are ttattagagggtggggtggattgt (sense) and
caaccccaaaccacaaccataa (antisense). The methylated PCR
product covers 151 bp extending from bp 167 to bp 317,
and the unmethylated product are 152 bp extending from
bp 167 to bp 318 [33]. The amplification was performed
in a thermocycler unit under the program conditions
(Hotstart Kit, Quiaqen) as follows: 95°C for 15 min; then
40 cycles of 95°C for 15 sec, 60°C for 30 sec, 72°C for 30
sec; and finally 10 min at 72°C. At least two independent
PCR amplifications were performed for each sample.
Cell cycle and vascular endothelial growth factor (VEGF) 
measurements
Analysis of cell cycle phases was performed using a Bec-
ton-Dickinson FACScan flow cytometer according to the
methods described previously [29] The cells were stained
with propium iodide solution (50 μg/ml) on ice, and at
least 10,000 cells were analyzed. For VEGF measurement,
the RPMI 8226 cells were plated at 0.3 × 106 cells/ml, the
cultures were incubated for designated time periods. The
contents of VEGF in the culture supernatants were deter-
mined with a VEGF ELISA kit (R & D System, Minneapo-
lis, MN, USA). The percent alteration of VEGF contents
from PHI-exposed cells was calculated and compared to
the control cultures.Journal of Hematology & Oncology 2008, 1:6 http://www.jhoonline.org/content/1/1/6
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Measurements of mitochondrial membrane potential and 
apoptosis
The effects of PHI treatment on mitochondrial membrane
potential was measured using a potential sensitive dye JC-
1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimida-
zolylcarbocyanine iodide). The JC-1 dye bears a delocal-
ized positive charge and enters the mitochondrial matrix
due to the negative charge established by the intact mito-
chondrial membrane potential [34,35]. In healthy cells,
JC-1 dye stains the mitochondria red due to formation of
J-aggregates. In apoptotic cells, JC-1 dye accumulates in
the cytoplasm in monomeric form (green fluorescence)
due to collapse of the mitochondrial membrane potential.
Stock solution of JC-1 (1 mg/ml) was prepared in DMSO
and freshly diluted with the supplied assay buffer.
RPMI8226 cells were incubated with medium containing
JC-1 (10 μg/ml) for 15 min at 37°C. Cells were washed
and re-suspended in 0.5 ml assay buffer and the fluores-
cence was measured using a Becton-Dickinson FACScan
flow cytometer. Carbonyl cyanide 4-(trifluorometh-
oxy)phenylhydrazone (CCCP; 25 μM), an uncoupler of
mitochondrial oxidative phosphorylation, was used as a
positive control.
Apoptotic cells were determined by the characteristic mor-
phology, and by the presence of DNA strand breaks
detected with terminal deoxynucleotidyl transferase-
mediated biotinylated UTP nick-end labeling (TUNEL).
The TUNEL detection of apoptosis in situ was performed
with a cell death detection kit (Roche Diagnostics, Indian-
apolis, IN). Briefly, cytospin preparations were fixed with
4% paraformaldehyde and incubated in Triton solution
for 4 min on ice. Cells incubated with the solution lacking
the terminal transferase were used as a negative control.
The slides were counter stained with 5% methyl green and
evaluated under a light microscope. The percentage of
apoptotic cells was calculated by counting at least 500
cells from multiple fields.
Western blot analysis
The expression levels of protein in RPMI 8226 were deter-
mined by Western blot analyses using standard proce-
dures as described previously [29]. Total proteins were
prepared from each culture condition with a lysis buffer
containing freshly prepared protease inhibitors. The pro-
tein contents of the lysates were determined by using the
BioRad Protein Assay kit (Bio Rad, Hercules, CA, USA)
with a BSA standard. Proteins were subjected to SDS-
PAGE, electrotransferred to nitrocellulose membrane, and
immunoblotted with specific antibodies. Antibodies
against acetyl-histone H3 were purchased from Upstate
Biotechnology (Lake Placid, NY). Antibodies against p16
and IL-6R were purchased from Santa Cruz (Santa Cruz,
CA, USA). β-actin was used as a loading control. Appropri-
ate HRP- conjugated secondary antibodies were used. The
reactive proteins were visualized using the ECL system.
Statistical analysis
The data are presented as mean ± S.D. from multiple inde-
pendent experiments. Results were evaluated by a two-
sided paired Student's t-test for statistical difference.
Results
PHI inhibits proliferation and causes G1 arrest of multiple 
myeloma cells
To evaluate the effects of PHI on the growth of myeloma
cells, the multiple myeloma cell line RPMI8226 was
exposed to PHI at various concentrations. PHI caused a
concentration- and time-dependent growth inhibition in
these cultures. A significant growth inhibitory effect could
be achieved with PHI at a concentration as low as 0.1 μM
(Figure 1A). A 37.1% decrease of cell density was observed
when 0.1 μM PHI was present in the cell culture. The cell
proliferation was further reduced to 50% of that of control
with PHI concentration at 0.5 μM. When the cells were
exposed to PHI at the concentration of 5 μM, the culture
became static. Morphological changes were also observed
after exposure of RPMI 8226 cells to PHI. The cells
appeared to have condensed chromatin, plasma mem-
brane blebbing and cell shrinkage, characteristics of apop-
tosis (data not shown). The apoptosis was also confirmed
by the significant increase of DNA strand breaks as meas-
ured by the TUNEL method (data not shown).
To study the effects of PHI on the cell cycle progression,
the distribution of cells in different cell cycle phases was
analyzed by flowcytometry. Figure 1B reveals a clear
decrease of the replicating cells in S- and G2M-phases after
PHI exposure for 48 hours at 0.5 μM (Figure 1B). The pro-
portion of S- plus G2M-phases after 96 hr was decreased
to 23.9%, as compared to 80.3% in the control cultures,
indicating an approximately 3-fold reduction in cell pro-
liferation. Along with the decrease of S- and G2M-phase
cells, the cells in G1 phases showed a concomitant
increase (Figure 1B). This is consistent with a G1-phase
arrest.
PHI induces p16 DNA hypomethylation
To explore the potential mechanisms of cell growth inhi-
bition by PHI, we examined the status of DNA methyla-
tion and protein expression of a tumor suppressor gene,
p16. Decitabine (5-aza-2-deoxy-cytidine), a known inhib-
itor of DNA methylation, was used as a positive control.
In myeloma cells, p16 is known to be inactivated, due to
aberrant CpG island methylation [6,7,32]. The status of
DNA methylation was measured by methylation- specific
PCR. Figure 2 reveals that the untreated cells have only the
methylated form of p16, and there was no detectable level
of the unmethylated form of p16. After exposure of theJournal of Hematology & Oncology 2008, 1:6 http://www.jhoonline.org/content/1/1/6
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cells to PHI at 0.5 μM for 10 days, the unmethylated form
became detectable, similar to that mediated by decitabine.
There appeared to be an increase of hypomethylation of
p16 when cells were exposed to higher concentrations of
PHI (Fig. 2). The results suggested that PHI induced p16
hypomethylation in a concentration-dependent manner.
PHI suppresses growth and causes cell cycle arrest of RPMI8226 myeloma cells Figure 1
PHI suppresses growth and causes cell cycle arrest of RPMI8226 myeloma cells. (A). PHI suppresses growth of 
RPMI8226 myeloma cells. The myeloma cells were cultured with or without phenylhexyl isothiocyanate (PHI) at varying con-
centrations for 24, 48 or 72 hours. The cell number was recorded at each time point. Diamond (♦), control; Square (■), 0.1 
μM; Triangle ( ), 0.5 μM; Dot (●); 5.0 μM. (B). PHI induces G1 growth arrest. The myeloma cells were cultured with 0.5 μM 
of PHI for 48 or 96 hours. The cellular DNA content was determined by flow cytometry. Values are means +/- SD from 3 inde-
pendent experiments. Open bar, G1 phase; Black bar, G2M phase; Grid bar, S phase.
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PHI inhibits histone deacetylation
We have previously shown that PHI can inhibit the his-
tone deacetylase and induces histone hyperacetylation in
HL-60 leukemia cells and prostate cancer cells [29-31].
The status of histone acetylation was examined in
RPMI8226 myeloma cells after exposure to PHI. The
acetylation of histone H3 was significantly increased in a
concentration- dependent manner (Fig 3).
PHI inhibits IL-6 receptor expression and reactivates p21 
expression
IL-6 mediated signaling pathway is known to be involved
in myeloma pathogenesis, and is one of the mechanisms
of drug resistance of myeloma cells [2,11]. We examined
the effects of PHI on the expression of IL-6 receptors in
RPMI8226 cells. PHI mediated a significant decrease of
the expression of IL-6 receptor subunits gp80 and gp130
(Fig. 4). The expression of both receptor subunits was sig-
nificantly reduced after 24 hr exposure to 5 μM PHI, and
nearly diminished by 48 hrs. There was also a time-
dependent increase of the level of p21 protein expression
after PHI treatment (Fig.4). The reactivation of p21
expression by PHI has been demonstrated in our labora-
tory in other cell lines [29,30].
PHI inhibits production of VEGF from myeloma cells
Angiogenesis has been considered as an important factor
for the post-initiation and progression of myeloma, i.e.
the metastasis of the tumor cells to the skeleton. We there-
fore analyzed the effects of PHI on the production of
VEGF from the myeloma cell line. Figure 5 shows that PHI
caused the suppression of VEGF production in a concen-
tration- and time-dependent manner. At 10 μM, a signifi-
cant 30% reduction of VEGF production was observed
PHI inhibits IL-6 receptor expression and reactivates p21  expression in RPMI8226 myeloma cells Figure 4
PHI inhibits IL-6 receptor expression and reactivates 
p21 expression in RPMI8226 myeloma cells. The 
RPMI8226 myeloma cells were cultured with 5 μM of PHI for 
24 and 48 hours, respectively. The proteins were extracted 
from the cell lysates. The expression level of IL-6 receptor 
subunits, gp80 and gp130, as well as p21 protein were deter-
mined by Western blot analysis as described in Material and 
Methods. β-actin level in the same blot was used as an inter-
nal loading control for protein amount.
gp130
gp80
ß-actin
p21
untreated   treated      treated
24 hr         48hr 
PHI induces p16 hypomethylation in RPMI8226 myeloma  cells Figure 2
PHI induces p16 hypomethylation in RPMI8226 mye-
loma cells. The myeloma cells were cultured with or with-
out phenylhexyl isothiocyanate (PHI) at varying 
concentrations for 10 days. Cellular DNA was extracted and 
bisulfite-converted as described in Material and Methods. 
Methylation-specific PCR was performed using primers spe-
cific for methylated and unmethylated DNA forms of p16, 
respectively. The PCR product was visualized after agarose 
gel electrophoresis. Decitabine (5-aza) was used as a positive 
control for DNA hypomethylation. M, methylated p16 frag-
ment; U, unmethylated p16 fragment. The 150 bp marker 
position was indicated.
  2.0      2.0 1.0      1.0 0.5   0.5 PHI   (   M)
 1.0      1.0    5-Aza  (   M)
M       U       M        U          M       U       M       U M       U    Marker
   150bp
PHI inhibits histone deacetylation in RPMI8226 myeloma cells Figure 3
PHI inhibits histone deacetylation in RPMI8226 mye-
loma cells. The RPMI8226 myeloma cells were cultured 
with two different concentrations of PHI for 72 hours. The 
proteins were extracted from the cell lysates. The status of 
histone H3 acetylation was determined by Western blot as 
described in Material and Methods. β-actin level in the same 
blot was used as an internal loading control for protein 
amount.
Acetylated H3
ß-actin
PHI          - 0.5            2
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PHI inhibits production of VEGF in RPMI8226 myeloma cells Figure 5
PHI inhibits production of VEGF in RPMI8226 myeloma cells. (A). The cells were incubated with varying concentra-
tion of PHI for 24 and 48 hours, respectively. VEGF production was determined as described in the Material and Methods. Dia-
mond (♦), control; Square (■), 0.1 μM; Triangle ( ), 5 μM; Cross (x), 10 μM. (B). Percent inhibition of VEGF production as 
compared with the control culture was calculated from the above experiments. Values are means +/- SD from 3 independent 
experiments. Open bar, 24 hours; Black bar, 48 hours.
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after 24 hr exposure, as compared to control cultures (p <
0.05). By 48 hrs, there was an approximately 70% reduc-
tion (p < 0.05).
PHI induces disruption of mitochondrial membrane 
potential
Previously we have demonstrated that PHI induced apop-
tosis through the activation of caspase-9, which often is
the result of disruption of mitochondrial membrane
potential. The latter led to the subsequent release of the
effector molecules for apoptosis [35]. To further character-
ize the mechanism of apoptosis in the myeloma cells
induced by PHI, we examined the status of mitochondrial
membrane potential by a flowcytometric method after
staining with JC-1, a dye that forms a color aggregate
depending on the membrane potential. CCCP, a known
agent that can cause disruption of mitochondrial mem-
brane potential, was used as a positive control. Exposure
of RPMI8226 cells to PHI caused a concentration-depend-
ent shift from red fluorescence to green fluorescence, indi-
cating the disruption of mitochondrial membrane
potential (Fig. 6). There was a two fold increase in the
number of cells with the disruption of mitochondrial
membrane potential when 5 μM PHI was present for 48
PHI causes disruption of mitochondrial membrane potential in RPMI8226 myeloma cells Figure 6
PHI causes disruption of mitochondrial membrane potential in RPMI8226 myeloma cells. The myeloma cells were 
treated with 5 μM and 10 μM of PHI, respectively for 48 hours. The cells were then stained with JC-1 dye. The mitochondrial 
membrane potential was measured by flowcytometry as described in the Material and Methods. The shift-down of fluores-
cence from Red to Green indicates the collapse of mitochondrial membrane potential. CCCP was used as a positive control 
for the disruption of mitochondrial membrane potential. The percent of cells with the disruption of mitochondrial membrane 
potential was indicated.
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hours. A 3.4-fold increase was observed when 10 μM PHI
was present for 48 hours. The results indicated that PHI-
induced apoptosis involves mitochondria.
Discussion
This study demonstrated that PHI can inhibit the prolifer-
ation of the myeloma cell line RPMI8226 and induce
apoptosis in a concentration as low as 0.5 μM. Most of the
cells became apoptotic at a PHI concentration of 5 μM.
These concentrations are lower than that required for
growth inhibition and apoptosis in HL60 leukemia cells
and prostate cancer cells that we have reported [29-31]. At
the above concentration we have shown that PHI was
nontoxic to normal human blood mononuclear cells [29].
We have initiated a protocol to investigate whether PHI
has activities on myeloma cells obtained directly from
patients.
In agreement with previous reports, p16 was found to be
hypermethylated in RPMI8226 cells [7,32]. PHI induced
hypomethylation of p16 at a concentration-dependent
manner. The hypomethylation was comparable to that
induced by decitabine, one of the two hypomethylating
agents that have been approved for the therapy of myelo-
dysplastic syndrome [36,37]. The reactivation of the
tumor suppressor gene p16 may at least in part be respon-
sible for the G1 arrest and apoptosis of RPMI8226 mye-
loma cells. There could be other genes and pathways that
are activated by PHI-induced hypomethylation, because
hypermethylation of tumor suppressor genes, such as
SOCS-1, p16, E-cadherin, DAP kinase, MGMT, were fre-
quently detected in myeloma cell lines as well as in clini-
cal specimens from patients with plasma cell disorders
[4,7]. The demethylation of p16 induced by PHI may
involve DNA methyltransferase, which is being currently
investigated.
Several HDAC inhibitors have been examined as a new
class of potential drugs for treating myeloma [19,24]. We
have recently reported that PHI is an inhibitor of HDAC
and can induce selective histone acetylation and methyla-
tion changes in human leukemia cells [29,30]. The current
study showed that PHI induced histone H3 hyperacetyla-
tion and p16 promoter hypomethylation. These findings
suggest that PHI has dual effects of epigenetic modulation
on both DNA and chromatin. The dual effects on DNA
and chromatin from a single agent may provide a syner-
gistic effect in reactivating p16 and other tumor suppres-
sor genes. DNA methylation and histone deacetylation are
linked in their actions for silencing gene expression. The
methylated CpG-binding protein (MeCP2) recruits
HDACs to specific promoter regions that induce the for-
mation of repressive chromatin structure and transcrip-
tion repression [32]. It would be interesting to study
whether the combination of PHI and azacytidine has syn-
ergistic activity toward inhibition of myeloma cells. Clin-
ical trials using a combination of HDAC inhibitors and
hypomethylating agents are already underway for the
therapy of patients with leukemia and myelodysplasia
[38].
It was previously shown that when two HDAC inhibitors,
SAHA and TSA, were combined, the cytotoxic effects on
multiple myeloma were enhanced, and apoptosis was in
part due to the disruption of mitochondrial membrane
potential by the HDAC inhibitors [35]. The current study
was in agreement with the above report. The combination
of PHI and SAHA may enhance even more the cytotoxic
effects on the myeloma cells due to the fact that PHI
induces DNA hypomethylation as well as histone hyper-
acetylation.
IL-6 and IL-6 receptor- mediated signaling pathway is crit-
ical for the survival and proliferation of myeloma cells [1].
Angiogenesis inhibitors, thalidomide and lenalidomide,
are new agents in the therapy of MM [1]. This study
showed that PHI can inhibit the expression of IL-6 recep-
tors and also reduce the cytokine VEGF produced by the
RPMI 8226 myeloma cells. The latter corroborates a previ-
ous report of another HDAC inhibitor, valproic acid, that
caused inhibition of VEGF production by RPMI8226 cells
[26]. These results indicate that PHI targets several critical
processes of myeloma survival and proliferation. One
limit of this study is that it focused on one cell line,
RPMI8226. Further experiments in more myeloma cell
lines and in vivo animal studies would give further
insights into the mechanisms and activities of PHI on
myeloma cells. More studies are needed to further charac-
terize this promising modulator of epigenetic processes
for its potential in clinical applications.
Conclusion
For the first time PHI was shown to induce both p16
hypomethylation and histone H3 hyperacetylation. We
conclude that PHI has dual epigenetic effects on p16
hypomethylation and histone hyperacetylation in mye-
loma cells and targets several critical processes of mye-
loma proliferation.
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